SHC Parenteral Nutrition (Adults) Competency 2025 - Online

Wednesday, October 1, 2025, 8:00 AM - Friday, January 1, 2027, 7:00 AM PT

Pharmacists need an update on parenteral nutrition prescribing and monitoring. This will be measured by passing rate on post-test evaluation. 

1. Describe the role of parenteral nutrition (PN)
2. Analyze appropriate indications for PN
3. Choose the best PN route based on the patient’s clinical status and nutrition needs
4. Define the major components of PN admixtures
5. Compare the roles of components in maintaining nutrition status
6. Differentiate key factors to consider in the initiation, administration and management of PN therapies
7. Illustrate strategies for holding parameters, monitoring, treating complications and considerations for discontinuation

 

Accreditation:  Sharp HealthCare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CPE Credit:  Sharp HealthCare designates this Enduring Materials for a maximum of 1 contact hours (1.00 CEUs).  Partial credit will not be awarded.  Pharmacists can verify their credits at  CPE Monitor within 30 days of completion of this activity.  UAN: 0571-0000-25-024-H01-P        

Cultural & Linguistic Competency and Implicit Bias Standards: This activity is in compliance with California Assembly Bill 1195 which requires that all CME activities comprising a patient care element include curriculum addressing the topic of cultural and linguistic competency and in compliance with California Assembly Bill 241 which requires that all CME activities incorporate educational components to address factors identified as impacting the provider’s patient populations and disparities potentially caused and exacerbated.

Mitigation of Relevant Financial Relationships

Sharp HealthCare adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education (ACE). Any individuals in a position to control the content of an ACE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.